Pipeline & Technology

Our Pipeline

Cara Therapeutics Drug Development

Drug Indication Preclinical Phase I Phase II Phase III Commercialization Rights*
Pruritus
Pruritus KORSUVA™ Injection
(Difelikefalin/CR845)
Pruritus CKD-HD Commercial Rights: US - Cara
EU / Other-VFMCRP#
US - Cara
EU / Other-VFMCRP#
Oral KORSUVA™
(Difelikefalin/CR845)
Pruritus CKD Stages III - V Commercial Rights: Cara
Cara
Oral KORSUVA™
(Difelikefalin/CR845)
Pruritus CLD Commercial Rights: Cara
Cara
Pain
Pain IV Difelikefalin/
CR845
Post-Op Setting Commercial Rights: Cara
Cara
Oral Difelikefalin/
CR845
Chronic Pain Commercial Rights: Cara
Cara
  1. *Commercialization rights to CR845 in all indications – Japan: Maruishi Pharma ; South Korea: CKD Pharma
  2. # VFMCRP and Cara have rights to promote in U.S. Fresenius Medical Care dialysis clinics under a profit share agreement
  3. CKD = Chronic Kidney Disease
  4. CKD- HD = Chronic Kidney Disease – Hemodialysis
  5. CLD = Chronic Liver Disease

 

The United Stated Food and Drug Administration (FDA) has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.